ProfileGDS5678 / 1416188_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 91% 90% 91% 90% 93% 91% 92% 92% 89% 88% 88% 88% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.2988191
GSM967853U87-EV human glioblastoma xenograft - Control 27.3846691
GSM967854U87-EV human glioblastoma xenograft - Control 37.2897190
GSM967855U87-EV human glioblastoma xenograft - Control 47.6713991
GSM967856U87-EV human glioblastoma xenograft - Control 57.3620190
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.6390793
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.3013191
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.620192
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.6395692
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1383389
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.8670188
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9595788
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8581788
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1306290